On the surface, the press release in and of itself may seem benign ... almost innocuous. When you start to proverbially put two and two together, however, this morning's news from View Systems Inc. (OTCBB:VSYM) could actually be early notice that things are about to change for the young, small company. By digging deeper into the details, it becomes clear that VSYM could become in Brazil what TASER International, Inc. (NASDAQ:TASR) and OSI Systems, Inc. (NASDAQ:OSIS) have become in the United States - security icons. View Systems shareholders could be on the same bullish receiving end of things that OSIS and TASR shareholders were on when each of those companies were experiencing a growth spurt a few years back.
That news: View Systems Inc. will be demonstrating its security hardware (weapons-detection walkthrough scanners, handheld metal detectors, and body-mounted video recorders/transmitters) in Brazil next month, with the help of its partner and distributor there, Armorin LLC.
Top Defensive Companies To Watch For 2015: Susquehanna Bancshares Inc.(SUSQ)
Susquehanna Bancshares, Inc., through its subsidiaries, provides retail and commercial banking, and financial services in the mid-Atlantic region. Its retail banking services include checking, savings, and club accounts, as well as check cards, debit cards, money market accounts, certificates of deposit, individual retirement accounts, home equity lines of credit, residential mortgage loans, home improvement loans, automobile loans, personal loans, and Internet banking services. The company?s commercial banking services comprise business checking accounts, cash management services, money market accounts, land acquisition and development loans, commercial loans, floor plan, equipment and working capital lines of credit, small business loans, and Internet banking services. It also offers commercial, property, and casualty insurance; and risk management programs for medium and large sized companies. In addition, it provides traditional trust and custodial services, as well a s acts as an administrator, executor, guardian, and managing agent for individuals, businesses, and non-profit entities. Further, the company offers investment advisory, asset management, and brokerage services for institutional and high net worth individual clients; and provides retirement planning services. Additionally, it engages in the equity management of assets for institutions, pensions, endowments, and high net worth individuals; and provides consumer vehicle financing services. The company operates 221 branches and 26 free-standing automated teller machines. Susquehanna Bancshares, Inc. was founded in 1982 and is based in Lititz, Pennsylvania.
Advisors' Opinion:- [By Johanna Bennett]
BB&T Corp. (BBT) agreed to buy Susquehanna Bancshares (SUSQ) for about $2.5 billion in cash and stock. Shares of BB&T fell 1.7%, while shares of Susquehanna surged 32.5% to end at $13.12.
- [By Rich Duprey]
Financial services holding company�Susquehanna Bancshares (NASDAQ: SUSQ ) announced yesterday its third-quarter dividend of $0.08 per share, the same rate it paid last quarter after raising the payout 14%, from $0.07 per share.
Hot International Companies To Buy Right Now: BioMarin Pharmaceutical Inc.(BMRN)
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.
Advisors' Opinion:- [By Lauren Pollock]
BioMarin Pharmaceutical Inc.(BMRN) said a U.S. Food and Drug Administration advisory panel recommended approval of the company’s enzyme-replacement therapy for patients with a rare inherited disorder that can hinder growth. In premarket trading, shares rose 5.7% to $70.75.
- [By Ben Levisohn]
Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.
- [By MONEYMORNING.COM]
There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search.
Questions to Answer Before You Buy In Does the drug fulfill an unmet need?
Alexion Pharmaceuticals Inc.'s (Nasdaq: ALXN) Soliris (eculizumab) is the only drug approved to treat paroxysmal nocturnal hemoglobinuria (PNH), an extremely rare, lethal blood disorder. It is also the only therapy approved to treat atypical hemolytic uremic syndrome (aHUS), a genetic condition that can result in sudden and progressive damage to vital organs, leading to stroke, heart attack, and kidney failure. Five years ago, ALXN shares were selling for about $18.50. They recently hit a high of $180.51 - thanks to Soliris, and Soliris alone. Is it a "breakthrough" drug?
A "Breakthrough Therapy" (BT) is actually a designation awarded by the FDA for a drug that "...is intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and [has] preliminary clinical evidence [that] indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." In 2012, the FDA granted Roche/Genetech's Gasyva a BT designation and then approved it for marketing in 2013. It treats chronic lymphocytic leukemia (CLL) and is expected to be a big blockbuster - as are the other three breakthrough therapies that were approved last year. Can its market produce blockbuster income?
This can mean a huge market, such as patients with high cholesterol - think Pfizer Inc.'s (NYSE: PFE) Lipitor (atorvastatin calcium), the bestselling drug of all time - or a small market that will pay for highly priced orphan drugs for rare diseases. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a company that specializes in the - [By Sean Williams]
BioMarin Pharmaceuticals (NASDAQ: BMRN )
BioMarin might as well be considered a long lost sibling of Alexion, since they are both focused on developing rare orphan drugs which have practically no competition and hefty annual price tags, often in six-figures. However, whereas Alexion is profitable, BioMarin has some "'splaining to do," as Desi Arnaz used to say. Estimates in the upcoming quarter call for sales growth of just 8% to $134 million with losses expected to widen to $0.29 per share. Naglazyme's 1% sales increase last quarter didn't impress at all, so it'll need Aldurazyme to really step up if it hopes to maintain its frothy valuation.
Hot International Companies To Buy Right Now: Nuveen Premium Income Municipal Fund 2 Inc (NPM)
Nuveen Premium Income Municipal Fund 2, Inc. (NPM) is a non-diversified, closed-end management investment company. The Fund seeks to provide current income exempt from regular federal income tax by investing primarily in a portfolio of municipal obligations issued by state and local government authorities or certain United States territories. Nuveen Asset Management (NAM) is the Fund's investment adviser. NAM is a wholly owned subsidiary of Nuveen Investments, Inc. Effective January 1, 2005, Nuveen Advisory Corp. (NAC) and its affiliate, Nuveen Institutional Advisory Corp. (NIAC), were merged into NAM.
Advisors' Opinion:- [By Chuck Carnevale]
Next, I turned to an evaluation of gross profit margin (gpm), net profit margin (npm), return on assets (roa), return on equity (roe) and return on invested capital (roi). The example below only includes gross and net profit margin, however, I review data on all the metrics stated above.
Hot International Companies To Buy Right Now: Energy Recovery Inc (ERII)
Energy Recovery, Inc. incorporated in April 1992, is engaged in developing, manufacturing and selling of energy recovery devices and circulation pumps primarily for uses in seawater desalination plants that use reverse osmosis technology. The Company's products are sold under the trademarks AquaBold, AquaSpire, ERITM, PXT, Pressure Exchanger, PX Pressure Exchanger, PEIT, Pump Engineering and Quadribaric. The Company develops and sells two main lines of energy recovery devices: PX pressures Exchanger devices and turbochargers. Each line includes a range of models and sizes to address the breadth of required process flow rates, plant designs and sizes. The company has two wholly owned subsidiaries: Energy Recovery Iberia, S.L. and ERI Energy Recovery Ireland Ltd. During the year ended December 2011, the Company merged three subsidiaries including, Osmotic Power, Inc.; Energy Recovery, Inc. International and Pump Engineering, Inc. into the parent company, Energy Recovery, Inc.
Energy recovery devices
The Company's PX offering includes: the PX-300 and PX-Q300; the 65 series (the PX-260, PX-220 and PX-180); the 4S series (PX-140S, PX-90S, PX-70S, PX-45S and PX-30S) and brackish PX devices (for the desalination of water with a lower concentration of salt than seawater). The Company's turbocharger offering includes: the HTCAT series (HTCAT-1800, HTCAT-2400, HTCAT-3600, HTCAT-4800, HTCAT-7200 and HTCAT-9600); the HALO line (HALO-50, HALO-75, HALO-100, HALO-150, HALO-225, HALO-300, HALO-450, HALO-500, HALO-600, HALO-900 and HALO-1200) and the LPT series for brackish water desalination applications (LPT-63, LPT-125, LPT-250, LPT-500, LPT-1000, LPT-2000 and LPT-3200).
High-pressure and Circulation pumps.
The Company manufactures and sells high-pressure feed, circulation and booster pumps for uses with its energy recovery devices in reverse osmosis desalination plants. The Company's line of pumps includes the AquaBold series (AquaBold 2x3x5, AquaBold 3x4x7 and ! AquaBold 4x6x9); the AquaSpire series (AquaSpire-300, AquaSpire-450, AquaSpire-600, AquaSpire-900, AquaSpire-1200, AquaSpire-1800, AaquaSpire-2400, AquaSpire-3600, AquaSpire-4800, AquaSpire-7200 and AquaSpire-9600) and a line of small circulation pumps.
Technical support and Replacement parts
The Company provides engineering and technical support to customers during product installation and plants commissioning. The Company also offers replacement parts and services for its PX devices and turbochargers. The Company's PX devices and turbochargers are also used to retrofit or replace older energy recovery devices in existing desalination plants.
The Company Competes with Flowserve Corporation (Flowserve) based in Irving, Texas and Fluid Equipment Development Company, Clyde Union Ltd., Duchting Pumpen Maschinenfabrik GmbH & Co KG, KSB Aktiengesellschaft, Torishima Pump Mfg. Co., Ltd. and Sulzer Pumps, Ltd.
Advisors' Opinion:- [By Antè´¸nio Costa]
Energy Recovery, Inc. (NASDAQ: ERII) broke out of a small consolidation area with heavy volume and will likely have the attention of the swing-traders in the next days.
Hot International Companies To Buy Right Now: MicroChannel Technologies Corp (MCTC)
MicroChannel Technologies Corporation, incorporated on February 28, 2005, is a development-stage company. The Company is focused on the identification, acquisition, and development of new and potentially commercial opportunities.
As of August 31, 2013, the Company is not engaged in any business operations. As of August 31, 2013, the Company had no revenues.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Bonamour Inc (OTCBB: BONI), Firstin Wireless Technology Inc (OTCMKTS: FINW) and Microchannel Technologies Corp (OTCBB: MCTC) have been attracting attention from variosu investment newsletters lately with at least two of these stocks being the subject of paid promotions. Of course, there is nothing wrong with properly disclosed paid promotions or investor relation types of activities as its up to investors and traders alike to do their due diligence. So how hot are these small cap stocks? Here is a quick reality check that might cool your appetite:
No comments:
Post a Comment